Navigation Links
PAREXEL International to Present at Robert Baird 2009 Healthcare Conference

BOSTON, Sept. 1 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the Robert Baird 2009 Healthcare Conference in New York, NY. James F. Winschel, Jr., Senior Vice President and Chief Financial Officer will be making a formal presentation on PAREXEL at 10:30 a.m. EDT on Wednesday, September 9, 2009.

A live webcast of this presentation will be available under the "Upcoming Events" section on PAREXEL's "Investors" homepage at A replay of the presentation will be available until November 24, 2009.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has over 9,275 employees. For more information about PAREXEL International visit

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

    CONTACT:  Jill Baker, Vice President of Investor Relations

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
2. PAREXEL International to Present at the Wachovia Equity Conference
3. PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
4. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention
5. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
6. PAREXEL Receives BioSingapore Award for Best Performing CRO
7. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
8. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
9. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
10. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
11. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):